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Zusammenfassung 
Hintergrund: 
In den letzten Jahren spielen molekulargenetische Ansätze in der Krebsfor-
schung sowohl für die Diagnostik als auch für die Therapie eine zunehmend 
wichtige Rolle. Hierbei sind insbesondere die sogenannten Onkogene und 
Tumorsuppressorgene von Bedeutung, deren deregulierte Expression maßgeb-
lich an Tumorinitiation und -progression beteiligt ist. In den letzten Jahren pos-
tulieren einige Autoren innerhalb der Gruppe der Tumorsuppressorgene eine 
Klasse von Molekülen, die vornehmlich Invasion und Streuung von Tumorzellen 
verhindern und als Metastasierungsrepressorgene ("metastasis repressor 
genes") bezeichnet werden. Zunehmende Beachtung erfahren sie vor allem 
wegen des möglichen Einsatzes als diagnostische Marker, die in der Lage sind, 
das Invasionsverhalten von Tumoren auf Grund molekulargenetischer Analysen 
vorherzusagen.  
Der Inter-alpha-trypsin Inhibitor (ITI) ist ein multifunktionaler Proteinkomplex der 
Extrazellulärmatrix und gehört der Gruppe der Plasmaprotease-Inhibitoren an. 
Die Inter-alpha-trypsin Inhibitoren werden in der Leber assembliert aus einer 
leichten Kette (dem Bikunin, kodierendes Gen ist das AMBP) und homologen 
schweren Ketten ("heavy chains" – ITIHs, von denen bisher fünf Gene be-
schrieben sind). Die leichte Kette ist verantwortlich für die Inhibition von Plas-
maproteasen wie Trypsin und Plasmin, während die schweren Ketten unter 
Vermittlung von TNFα-induziertem Protein 6 (TNFAIP6) kovalent an Hyaluron-
säure gebunden werden und diese zu Fibrillen vernetzen, die wichtiger Be-
standteil der Extrazellulärmatrix sind. Beiden Strukturelementen werden me-
tastasierungsrepressive Eigenschaften zugeschrieben, die sowohl in vitro als 
auch im tierexperimentellen Modell bestätigt werden konnten. Für Bikunin 
scheint die Unterdrückung zellgebundener Plasmin-Aktivität für diesen Effekt 
verantwortlich zu sein, während die genauen Mechanismen bei den ITIHs im 
Detail nicht verstanden sind; aktuelle Modelle gehen von einer Stabilisierung 
der Extrazellulärmatrix aus, die eine Barriere für die Tumorinvasion darstellt. 
Bisher verfügbare Daten belegen eine wichtige Rolle der ITIHs für Entzün-
dungsprozesse und Tumorinvasion; systematische Daten über deregulierte 
ITIH-Expression in humanen Tumoren sind bisher jedoch nicht verfügbar. 
Zielsetzung: 
Die vorliegende Studie untersucht systematisch deregulierte Expressionsmuster 
der ITIH-Moleküle in humanen soliden Tumoren: Eine Herabregulation in zahl-
reichen Tumorentitäten kann als Beleg für tumorsuppressive und/oder metasta-
sierungsreprimierende Eigenschaften angesehen werden. Darüber hinaus wird 
exemplarisch die Herabregulation von ITIH2 im Mammakarzinom herausge-
griffen, um die Daten mit unabhängigen Methoden zu bestätigen und die klini-
sche Relevanz der systematisch erhobenen Expressionsdaten zu untersuchen. 
Material und Methoden: 
Die Untersuchung der differenziellen Genexpression sowohl der ITIH-Familie 
als auch von AMBP und dem Reaktionspartner TNFAIP6 in 13 verschiedenen 
humanen Tumorentitäten (Karzinome von Mamma, Endometrium, Ovar, Cervix, 
Magen, Dünndarm, Colon, Rektum, Lunge, Schilddrüse, Prostata, Niere und 
Pankreas) erfolgte mittels RNA-Expressionsanalysen (an einem Multiple Tissue 
Northern Blot, MTN), cDNA-Dot-Blot-Expressionsanalysen (an einem sog. 
Cancer Profiling Array, CPA, für 241 Paare von Tumor- und Normalgewebe 
derselben Patienten), semiquantitativer RT-PCR (an Gewebeproben von Brust-
krebspatientinnen) sowie immunhistochemischer Färbungen (im Tissue Micro 
Array für 185 invasive duktale Mammakarzinome). Statistisch wurde der Zu-
sammenhang zwischen den Ergebnissen der quantitativen immunhistoche-
mischen Auswertung für die Expression von ITIH2 und den verfügbaren 
klinisch-pathologischen Daten in Kreuztafeln (zweiseitiger exakter Test nach 
Fisher) und Überlebensanalysen (Verfahren nach Kaplan-Meier) untersucht. 
Ergebnisse und Diskussion: 
Die Untersuchungen zeigen eine klare Herabregulation der ITIH-Gene in zahl-
reichen humanen soliden Tumoren unterschiedlicher Organe wie Mamma, 
Colon, Lunge und Niere. Die ITIH-Gene stellen daher eine Familie putativer 
Tumorsuppressor- bzw. Metastasierungsrepressorgene dar, die künftig eine 
tiefergehendere Charakterisierung erfahren sollten. Für eine erste detaillierte 
Untersuchung wurde die Herabregulation der ITIH2-Expression in 70 Prozent 
der untersuchten Brustkrebsfälle (n=50 im CPA) ausgewählt, die mittels semi-
quantitativer RT-PCR an einem unabhängigen Patientenkollektiv (n=36) bestä-
tigt werden konnte. Die Expressionsstärke des zugehörigen Proteins ITIH2 
wurde daraufhin immunhistochemisch an einem Tissue Micro Array mit 185 
Gewebeproben zumeist invasiv duktaler Mammakarzinome untersucht. Hier 
zeigte sich eine starke Korrelation (p<0,001) zwischen der Expression des 
matrixstabilisierenden ITIH2-Proteins und dem Status des Östrogen-Rezeptors, 
dessen Expression einen hohen prognostischen Wert besitzt. Eine Heraufre-
gulation der ITIH2-Expression durch Östrogen-Gabe konnte im Zellkulturmodell 
bereits durch andere Arbeitsgruppen nachgewiesen werden; weitere funktio-
nelle Studien, insbesondere zu den molekularen Interaktionen, sind jedoch 
dringend erforderlich. 
Ein statistisch signifikanter Zusammenhang zwischen der Stärke der ITIH2-
Expression und dem Gesamt- oder rezidivfreien Überleben der Mammakarzi-
nom-Patientinnen konnte bisher nicht nachgewiesen werden, obgleich sich in 
der Kaplan-Meier-Analyse ein entsprechender Trend zeigte; das heißt ITIH2-
negative Tumoren besitzen tendenziell eine schlechtere Prognose (p=0,386). 
Das Verfehlen des Signifikanzniveaus könnte auf Redundanzen in der funktio-
nellen Bedeutung von ITIH2 und ITIH5 zurückzuführen sein, die beide eng 
benachbart auf Chromosom 10p15 liegen. Für diese Interpretation spricht fer-
ner, dass für die Expression von ITIH5 bereits eine hoch signifikante Korrelation 
von Expressionsverlust und kürzerer Gesamtüberlebensdauer nachgewiesen 
werden konnte. 
Zusammenfassend zeigen die Experimente eine deutliche Herabregulation der 
ITIH-Moleküle in zahlreichen humanen soliden Tumoren, die als Beleg für 
tumorsuppressive bzw. metastasierungsreprimierende Eigenschaften verstan-
den werden kann. Damit ist für diese Genfamilie erstmals in einer systemati-
schen Expressionsstudie eine hoch differenzielle Expression nachgewiesen 
worden. Eine weitergehende Analyse einzelner Gene in verschiedenen Tumor-
entitäten ist jetzt notwendig, um die klinische Relevanz aufzuzeigen und den 
Weg zu ebnen für einen möglichen diagnostischen oder therapeutischen Ein-
satz in der Zukunft. Insbesondere für den diagnostischen Einsatz erscheint es 
vielversprechend, durch molekulargenetische Analyse spezifischer Tumoren 
weitere Marker zu identifizieren, mit denen sich deren Invasionsverhalten ab-
schätzen lässt. Mit derartigen Informationen können in der Zukunft für den ein-
zelnen Patienten besser angepasste Therapien ausgewählt werden, die insbe-
sondere der Aggressivität des Tumors Rechnung tragen. 
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Abstract
Background: The inter-alpha-trypsin inhibitors (ITI) are a family of plasma protease inhibitors, assembled from
a light chain – bikunin, encoded by AMBP – and five homologous heavy chains (encoded by ITIH1, ITIH2, ITIH3,
ITIH4, and ITIH5), contributing to extracellular matrix stability by covalent linkage to hyaluronan. So far, ITIH
molecules have been shown to play a particularly important role in inflammation and carcinogenesis.
Methods: We systematically investigated differential gene expression of the ITIH gene family, as well as AMBP
and the interacting partner TNFAIP6 in 13 different human tumor entities (of breast, endometrium, ovary, cervix,
stomach, small intestine, colon, rectum, lung, thyroid, prostate, kidney, and pancreas) using cDNA dot blot
analysis (Cancer Profiling Array, CPA), semiquantitative RT-PCR and immunohistochemistry.
Results: We found that ITIH genes are clearly downregulated in multiple human solid tumors, including breast,
colon and lung cancer. Thus, ITIH genes may represent a family of putative tumor suppressor genes that should
be analyzed in greater detail in the future. For an initial detailed analysis we chose ITIH2 expression in human
breast cancer. Loss of ITIH2 expression in 70% of cases (n = 50, CPA) could be confirmed by real-time PCR in an
additional set of breast cancers (n = 36). Next we studied ITIH2 expression on the protein level by analyzing a
comprehensive tissue micro array including 185 invasive breast cancer specimens. We found a strong correlation
(p < 0.001) between ITIH2 expression and estrogen receptor (ER) expression indicating that ER may be involved
in the regulation of this ECM molecule.
Conclusion: Altogether, this is the first systematic analysis on the differential expression of ITIH genes in human
cancer, showing frequent downregulation that may be associated with initiation and/or progression of these
malignancies.
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The inter-alpha (globulin) inhibitor (ITI) family (more
commonly called the family of inter-alpha-trypsin inhibi-
tors) is composed of serine protease inhibitors that are
assembled from two precursor proteins: a light chain and
either one or two heavy chains[1,2]. While there is only
one type of light chain, there are different homologous
heavy chains (ITIHs), to date consisting of five members
(Table 1).
The light chain is encoded by alpha-1-microglobulin/
bikunin precursor (AMBP), which also codes for alpha-1-
microglobulin, a member of the lipocalin superfamily
that is not functionally or structurally related to the ITI
family[3]. ITI light chain contains two tandem-repeats of
kunitz type domains and has thus been assigned the name
"bikunin"[4]. The family of heavy chains (ITIHs), on the
opposite, is encoded by five genes located on two different
chromosomes [5-7]: ITIH1, ITIH2, ITIH3, ITIH4, and
ITIH5. Of these, ITIH1, ITIH3, and ITIH4 map to a closely
linked region on chromosome 3p21 [6] whereas ITIH2
und ITIH5 are tandemly arranged on chromosome
10p15[7]. During assembly of the mature ITI protein in
the liver, the precursor proteins for ITIH1-3 and bikunin
undergo extensive posttranslational modifications[8],
mainly involving trimming of the C-terminal ends [3].
However, the conserved cleavage site of these heavy
chains is absent in ITIH4[3], thus preventing a bond with
bikunin. Interestingly, the heavy chains (mostly ITIH1
and ITIH2) are linked to bikunin via a single chondroitin
sulfate chain[1,9], making ITI a both structurally and
functionally unique proteoglycan with a plasma protease
inhibitory activity [9], which resides solely in the bikunin
part of the molecule[3]. On the other hand, the only func-
tion known so far of the heavy chains is the covalent link-
age to hyaluronic acid (HA)[10], which is a major
component of the extracellular matrix (ECM), but is also
secreted into body fluids, such as blood and lymph fluid.
The transfer of the ITI heavy chains – due to this linkage
also called serum-derived hyaluronan-associated protein
(SHAP)[10] – onto HA requires tumor necrosis factor
alpha induced protein 6 (TNFAIP6), also known as TNF
stimulated gene (TSG-6) [11]. TNFAIP6 not only potenti-
ates the anti-plasmin activity of ITI [12], but forms a stable
complex [13] with ITIH and HA during the transesterifica-
tion reaction[14], specifically[15] enhancing the transfer
of the heavy chains as a catalytic factor in the presence of
calcium ions [16] (for a review on TNFAIP6 see Ref. [17]).
In addition, the bikunin-chain is required for the linking
process in the sense of a "SHAP-presenting molecule"[2].
The main function of ITIH is proposed to be an essential
factor in the stabilization of the ECM[1] (extensively
investigated in cumulus oophorus cells[18]), based on the
covalent linkage of HA to the heavy chain, producing so-
called "cable-like structures"[2].
For a long period of time, the focus of attention has been
the urinary trypsin inhibitory activity, which originally led
to the discovery of the ITI molecule. An influence on cal-
cium oxalate cristallization and other renal and postrenal
processes has been investigated in depth[19]. In the past
two decades, however, the role of ITI in a broad range of
both physiological and pathological conditions could be
elucidated. Although its specific plasma-proteinase inhib-
Table 1: Family of human Inter-alpha-Inhibitor genes (and TNFAIP6)
Official 
Symbol
Official Name Other Aliases Chromosomal 
Localisation
ITIH1 inter-alpha (globulin) inhibitor H1 H1P, IATIH, IGHEP1, Inter-alpha-inhibitor heavy chain 1, Inter-alpha-
trypsin inhibitor complex component III, Inter-alpha-trypsin inhibitor 
heavy chain H1 precursor, ITIH, ITI heavy chain H1, Serum-derived 
hyaluronan-associated protein, SHAP
3p21.2-p21.1
ITIH2 inter-alpha (globulin) inhibitor H2 H2P, IGHEP2, Inter-alpha-inhibitor heavy chain 2, Inter-alpha-trypsin 
inhibitor complex component II, Inter-alpha-trypsin inhibitor heavy 
chain H2 precursor, ITI heavy chain H2, Serum-derived hyaluronan-
associated protein, SHAP
10p15
ITIH3 inter-alpha (globulin) inhibitor H3 Inter-alpha-inhibitor heavy chain 3, Inter-alpha-trypsin inhibitor heavy 
chain H3 precursor, ITI heavy chain H3, Serum-derived hyaluronan-
associated protein, SHAP
3p21.2-p21.1
ITIH4 inter-alpha (globulin) inhibitor H4 
(plasma Kallikrein-sensitive 
glycoprotein)
GP120, H4P, IHRP, Inter-alpha-inhibitor heavy chain 4, Inter-alpha-
trypsin inhibitor family heavy chain-related protein, Inter-alpha-trypsin 
inhibitor heavy chain H4 precursor, ITI heavy chain H4, ITIHL1, 
PK120, PK-120, Plasma kallikrein sensitive glycoprotein 120
3p21-p14
ITIH5 inter-alpha (globulin) inhibitor H5 Inter-alpha trypsin inhibitor 10p15
AMBP alpha-1-microglobulin/bikunin 
precursor
AMBP protein precursor, HCP, ITI, ITIL, UTI 9q32-q33
TNFAIP6 tumor necrosis factor, alpha-induced 
protein 6
Hyaluronate-binding protein, TNF-stimulated gene 6 protein, TSG6, 
Tumor necrosis factor-inducible protein TSG-6 precursor
2q23.3
Official and alias names as found on the National Library of Medicine Website [48].Page 2 of 15
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inhibitors[20], a strong involvement of ITI in inflamma-
tion as well as in carcinogenesis and metastatic processes
can be postulated based on the published data available.
In the inflammation setting, ITI family members have
been demonstrated to be both positive and negative acute
phase proteins[2] under various conditions such as pan-
creatitis[21], polyarthritis[22], myocardial infarc-
tions[23], colitis[24], or sepsis[25,26], presenting
possibilities for diagnostic and therapeutic purposes (e.g.
administration of ITI in systemic sepsis[25,27] or as a pro-
tective agent in anthrax intoxication[28]). On the other
hand, there is strong evidence that all members of the ITI
family play an important role in different aspects of malig-
nant processes. The proteinase inhibitory activity of
bikunin suggests an influence on cell growth and metasta-
sis of tumor cells[1,29-31], as especially cell-bound plas-
min activity has been shown to play a key role in both
degradation of the ECM[32] and angiogenesis[33]. The
ITI heavy chains, as described above, most effectively sta-
bilize the ECM and have been shown to be involved in
processes such as tumor invasion[34] and metastasis [35].
For example, ITIH1 and ITIH3 have been shown to
increase cell attachment in vitro and to reduce the number
of metastases in a murine in vivo model [36]. In addition,
ITIH5 has been proven to be a novel prognostic marker in
invasive node-negative breast cancer, demonstrating its
involvement in tumor progression, invasion, and metas-
tasis[37].
Although these results clearly suggest that all members of
the ITI family may contribute to carcinogenesis via dereg-
ulated gene expression (hence influencing most impor-
tant cellular regulation mechanisms, such as proliferation,
differentiation, apoptosis, and extracellular matrix stabil-
ity), to date there has been no approach to systematically
investigate differential gene expression of the ITI family in
human cancer. In the present study, we address the issue
of up- or downregulation of ITI family genes, focussing on
the five heavy chains, their light chain partner bikunin
(encoded by AMBP) and their important functional regu-
lator TNFAIP6. Using cancer profiling arrays (CPAs), we
quantitatively analyzed expression of these seven genes in
a large panel of normal and malignant human tissues. We
show that the expression patterns of ITIH molecules are
clearly deregulated in a variety of human cancers, provid-
ing further evidence for their potential role as tumor sup-
pressor and/or metastasis repressor genes.
Methods
Clinical Materials
Samples of breast cancer specimens (n = 36) for real-time
PCR analysis were obtained from patients treated by pri-
mary surgery for breast cancer at the University Hospitals
of Aachen, Jena and Regensburg, Germany. All patients
gave informed consent to participate in the study. Tumor
material was snap-frozen in liquid nitrogen immediately
after surgery. Hematoxylin and eosin stained sections
were prepared for assessment of the percentage of tumor
cells, only samples with greater than 70% tumor cells were
selected for analysis. Frozen tissue samples were homoge-
nized in liquid nitrogen and dissolved in lysis buffer fol-
lowed by RNA isolation using TRIzol (Gibco-BRL,
Glasgow, UK) according to the protocol supplied by the
manufacturer. Clinicopathological data are presented in
Table 2.
A breast cancer tissue microarray was constructed as
described before [38,39], including 28 normal tissue sam-
ples, 185 invasive carcinomas, and 2 carcinomas in-situ.
All patients gave informed consent to participate in the
study. Clinical follow-up, provided by the Central Tumor
Registry Regensburg, Germany, was available for all breast
cancer patients with a median follow-up period of 79
months (0–148 months). Clinicopathological data are
presented in Table 2.
RNA expression analysis using Multiple Tissue Northern 
Blot – MTN
Tissue specific expression of each gene was analyzed using
Human Multiple Tissue Northern Blot I and Blot II (Prod-
uct no. 636806 and 636805, respectively; Clontech, Hei-
delberg, Germany). Each MTN consisted of eight lanes
from different human tissues, containing approximately 2
μg of poly A+ RNA per lane. RNA was run on denaturing
formaldehyde 1.0% agarose gels, transferred to a nylon
membrane by Northern blotting, and fixed by UV irradia-
tion. Lanes 1–8 on MTN I contain, in order, RNA from 1)
heart, 2) brain, 3) placenta, 4) lung, 5) liver, 6) skeletal
muscle, 7) kidney, 8) pancreas. Lanes 1–8 on MTN II con-
tain, in order, RNA from 1) spleen, 2) thymus, 3) prostate,
4) testis, 5) ovary, 6) small intestine, 7) colon (no
mucosa), 8) peripheral blood leukocytes (PBL).
cDNA probes for hybridization were generated by PCR
using commercially available normalized cDNA panels
derived from different human tissues (Product no.
636742, Clontech, Heidelberg, Germany[40]). RT-PCR
was performed on a Peltier Thermal Cycler-200 (Biozym,
Hamburg, Germany), using intron-spanning primers.
Primers and cDNAs used for each probe are presented in
Table 3. Amplified cDNA fragments were purified using
the QIAquick PCR purification Kit (Qiagen, Hilden, Ger-
many) in order to obtain the gene-specific cDNA probes.
Hybridization was then performed using 25 ng of the
gene-specific 32P-labeled cDNA probes. These gene-spe-
cific cDNA fragments were radiolabeled using a Meg-
aprime labeling kit (Amersham Biosciences,
Braunschweig, Germany), hybridized overnight at 65°CPage 3 of 15
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delberg, Germany), washed, and exposed to Kodak XAR-5
X-ray film with an intensifying screen (Eastman Kodak
Co., Rochester, NY, USA).
The specificity of each hybridization probe was deter-
mined by the co-hybridization of nylon membranes con-
taining different concentrations of spotted cDNA probe:
20 pg, 2 pg, and 0.2 pg of cDNA from each gene were
diluted in 3 μl of 20 × SSC buffer, heat-denatured for 5
min by boiling and then quenched on ice. Denatured
cDNAs were spotted on Hybond N+ membranes (Amer-
sham Biosciences, Freiburg, Germany) and fixed by UV
irradiation for 3 minutes. These membranes were treated
during filter hybridization, washing and exposition
exactly like the MTNs.
Expression analysis using Cancer Profiling Array – CPA
Expression of the five heavy chain genes (ITIH1, ITIH2,
ITIH3, ITIH4, and ITIH5) and the light chain gene
(AMBP), as well as TNFAIP6 were analyzed using the Can-
cer Profiling Array (Product No. 631761; Clontech, Hei-
Table 2: Clinicopathological and immunohistochemical characteristics of primary breast carcinomas
Variable Categorization IHC Realtime PCR
n1 % n1 %
Clinicopathological factor:
Age at diagnosis
Median, range (years) 57.5 (25–82) 57.5 (28–85)
≤ 50 years 54 29.2 10 27.8
> 50 years 128 69.2 26 72.2
unknown 3 1.6 0 0
Tumor stage2
pT1 46 24.9 15 41.7
pT2 92 49.7 16 44.4
pT3 13 7.0 0 0
pT4 30 16.2 4 11.1
pTx3 4 2.2 1 2.8
Lymph node status2
pN0 71 38.4 19 52.8
pN1–3 104 56.2 15 41.7
pNx3 10 5.4 2 5.6
Grading
G1/G2 100 54.1 19 52.8
G3 80 43.2 15 41.7
Gx3 5 2.7 2 5.6
Histological type
ductal 145 78.4 34 94.4
lobular 13 7.0 1 2.8
other 19 10.3 1 2.8
unknown 8 4.3 0 0
Immunohistochemistry (IHC):
Estrogen receptor status
negative (IRS4 0–2) 49 26.5 11 30.6
positive (IRS 3–12) 97 52.4 21 58.3
unknown 39 21.1 4 11.1
Progesterone receptor status
negative (IRS4 0–2) 107 57.8 12 33.3
positive (IRS 3–12) 49 26.5 20 55.6
unknown 29 15.7 4 11.1
HER2 expression status
negative (0–1+) 120 64.9 6 16.7
positive (2+-3+) 38 20.5 5 13.9
unknown 27 14.6 25 69.4
Characteristics of primary breast carcinomas used for ITIH2 immunohistochemistry (n = 185) and real-time PCR (n = 36) analysis.
1Only female patients with primary invasive breast cancer were included. 2According to UICC: TNM Classification of Malignant Tumours (2002) 
[65]. 3x = status unknown. 4IRS = Immunoreactivity score according to Remmele and Stegner (1987) [47].Page 4 of 15
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cDNAs and corresponding normal tissue from the same
patient [44].
The Cancer Profiling Array (CPA) consisted of 511 dots
with 494 cDNAs synthesized from various human tumors
and corresponding normal tissue specimens, i.e. 241
tumor and 241 matched normal tissue specimens as well
as 12 cDNAs from metastases corresponding to 12 of the
tumor/normal pairs. The following 241 matched tumor/
normal tissue cDNA pairs and 12 matching metastases
were included on the CPA: 50 breast cancer/50 normal/
three matching metastases, 42 uterine cancer/42 normal/
two matching metastases, 35 colon cancer/35 normal/
four matching metastases, 27 gastric cancer/27 normal
stomach, 14 ovarian cancer/14 normal/two matching
metastases, one cervical cancer/one normal, 21 lung can-
cer/21 normal, 20 renal cancer/20 normal, 18 rectal can-
cer/18 normal/one matching metastase, two small
intestine cancer/two normal, six thyroid cancer/six nor-
mal, four prostate cancer/four normal, one pancreatic
cancer/one normal. Each cDNA pair was independently
normalized based on the expression of four housekeeping
genes (ubiquitin, 23 kDa highly basic protein, β-actin and
glutamate dehydrogenase) and immobilized in separate
dots. Patient age, histological type, disease stage, tumor
size, node status, and presence or absence of metastases
for each specimen is supplied with the product and can be
obtained from the manufacturer upon request.
Hybridization of CPA was performed as described above
for the Multiple Tissue Northern blot. The tumor/normal
intensity ratio was calculated using a Typhoon 9410 High
Performance Imager (GE-Healthcare, Chalfont St. Giles,
UK) and normalized against the background. We defined
a gene as differentially expressed in a given tumor entity if
a common deregulation (two-fold up- or down-regula-
tion according to the well-established fold change two
approach, FC2) was detectable in at least 50% of tumor
tissue samples analyzed. Fold changes between 0.5 and
2.0 were considered as not differentially expressed.
Semiquantitative Real-Time PCR
Semiquantitative PCR was performed using the LightCy-
cler system together with the LightCycler DNA Master
SYBR Green I Kit (Roche Diagnostics, Basel, Switzerland).
Reaction volumes of 20 μl consisted of the following com-
ponents: 25 mM MgCl2, 10 μM forward primer, 10 μM
reverse primer, 2 μl LightCycler DNA Master SYBR Green
I and 1 μl of cDNA as PCR template. Gene expression was
quantified by the comparative CT method, normalizing
CT-values to the housekeeping gene GAPDH and calculat-
ing relative expression values[45].
Primer sequences for ITIH2 expression analysis were: for-
ward 5'-ACC AGG TCT CCA CTC CAT TG-3'; reverse 5'-
ATC CTG CAA GTC GTC CAT CT-3' (230 bp product size)
and for the reference gene GAPDH: 5'-GAA GGT GAA GGT
CGG AGT CA-3'; reverse 5'-TGG ACT CCA CGA CGT ACT
CA-3' (108 bp product size). The cycling conditions were
set up to an initial denaturation at 95°C for 15 min, fol-
lowed by 40 cycles with denaturation at 95°C for 20 s,
annealing at 60°C for 20 s and elongation at 72°C for 30
s. To verify the specificity of the PCR products, melting
curve analyses were performed. The relative gene expres-
sion levels were standardized to the expression level of a
normal breast tissue sample that contained approximately
50% of epithelial cells (tumors generally contained >70%
of tumor cells). To ensure experiment accuracy, all reac-
tions were performed in triplicates.
Immunohistochemistry
Whole tissue sections or tissue microarrays (TMAs),
respectively were stained with ITIH2 antibody which has
Table 3: Primers used to generate cDNA probes for dot blot hybridization
Gene Primers Product Size (bp) Tissue Source
ITIH1 5'-AAA GGG TCA TGT GCT GTT CC-3' 1121 liver
5'-ACC CAT AGT CCA GCG ACA TC-3'
ITIH2 5'-TGT TCA GAT CCC CAA AGG AG-3' 1169 liver
5'-ATG GAG TGG AGA CCT GGT TG-3'
ITIH3 5'-GCT GAG GCC TCT TTC ATC AC-3' 1019 liver
5'-TCC TTC ATG TCC ACC TCC TC-3'
ITIH4 5'-CTT CAA GGG CTC AGA GAT GG-3' 1141 liver
5'-GTC AGT GTC ACG CAG AAG GA-3'
ITIH5 5'-GAG GCC AAG TCT GCA TCT TC-3' 1010 placenta
5'-GAT GAC TCT GCT CGG TGT GA-3'
AMBP 5'-AGC TCC TCA TCA CCA TCA CC-3' 913 liver
5'-TTC TTC ACC AGC TGC TCC TT-3'
TNFAIP6 5'-AAG GAT GGG GAT TCA AGG AT-3' 781 skeletal muscle
5'-TGG CTA AAT CTT CCA GCT AAA AA-3'Page 5 of 15
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directed against the C-terminal region of ITIH2 protein
were generated by immunizing rabbits with the synthetic
oligopeptide PGKDPEKPEASMEVK coupled to KLH
(Sheldon Biotechnology Centre, McGill University, Mon-
treal, Canada). For immunohistochemistry, tissue sec-
tions were deparaffinized in xylene, rehydrated in a
decreasing ethanol series and pre-incubated with peroxi-
dase blocking solution. Staining with ITIH2 antibody was
performed in a dilution of 1:600 (no pre-treatment for
antigen retrieval), followed by a second-step incubation
with Dako's HRP, Rabbit/Mouse (ENV) reagent, using the
Dako REAL™ EnVision™ Detection System K5007 (Dako,
Glestrop, Denmark). Reaction was visualized by Dako
REAL™ DAB+ Chromogen. Sections were counterstained
with hematoxylin, dehydrated in an increasing ethanol
series and mounted with Vitro Clud (Langenbrinck,
Emmendingen, Germany) The application of primary
antibodies was omitted in negative controls, while liver
sections (as tissue with the strongest ITIH2 expression)
were used as positive controls. Sections were examined
and scored by a pathologist, using a semiquantitative
immunoreactive score (IRS) as described previously[47].
Mean dye intensity was assessed using the following scale:
0, negative; 1, low; 2, middle; and 3, strong. The percent-
ages of stained cells varied as follows: 0, negative; 1,
<10%; 2, 10% to 50%; 3, 51% to 80%; 4, >80% positive
cells. The product of both summands yields a total score
ranging from 0 to 12 points. According to the scores, tis-
sues were classified as having weak (0–4 points) or strong
(6–12 points) ITIH2 expression.
Statistical analysis of clinicopathological patient data
Statistical analyses were completed using SPSS version
14.0 (SPSS, Chicago, IL, USA). Differences were consid-
ered statistically significant when P values were <0.05.
Cross tables with clinicopathological characteristics versus
ITIH2 staining were established, using Fisher's exact test
(two-sided) to evaluate significancy. Overall survival (OS)
and recurrence-free survival (RFS) curves comparing
patients with strong versus weak staining in immunohisto-
chemistry analysis were calculated using the Kaplan-Meier
method, with significance evaluated by two-sided log-
rank statistics. OS and RFS were measured from time of
surgery until tumor-related death or recurrence, respec-
tively. Patients were censored at the time of their last
tumor-free clinical follow-up appointment or at their date
of death not related to the tumor.
Results
Expression analysis of the ITIH gene family in 13 different 
human tumor entities and normal human tissues
Expression of ITIH gene family members (ITIH1, ITIH2,
ITIH3, ITIH4, and ITIH5) as well as two additional genes
(AMBP and TNFAIP6) encoding proteins that regulate
ITIH functions were analyzed in human benign and
malignant tissues by two different methods. First, each of
the gene probes (except for ITIH5, which we have pub-
lished before[7]) was hybridized to a Northern blot con-
taining poly A+ RNA derived from 16 different human
normal tissues (Multiple Tissue Northern Blot – MTN) to
determine its transcript size(s) and the specificity of the
probes later used for cDNA dot blot hybridization. Figure
1 demonstrates that ITIH mRNAs are predominantly
expressed in the liver with the exception of ITIH5, which
is most abundantly expressed in placental tissue[7]. ITIH3
and ITIH4, in addition, show abundant expression in
ovarian and pancreatic tissue, respectively. All six probes
presented a specific hybridization signal on Northern blot
and the determined sizes of the corresponding mRNA
transcripts were in good accordance with mRNA sizes
annotated on the National Library of Medicine Webpage
[48].
Next, these gene probes were used for dot blot hybridiza-
tion on a Cancer Profiling Array (CPA). The CPA contains
spotted cDNAs from 241 tumor and 241 matched normal
tissue samples representing 13 different human tumor
entities. These dot blot arrays are highly sensitive in the
detection of even rare transcripts since a considerable
amount of cDNA (10–50 μg) has been spotted in a very
small area (1 mm in diameter). In analysis of differential
expression, the percentage of up-regulation or down-regu-
lation was defined according to the well-established fold
change two approach (FC2, see Material and Methods).
Interestingly, each member of the ITIH gene family except
ITIH1 (data not shown) exhibited highly differential
Expression of the ITIH gene family and AMBP and TNFAIP6 genes in normal human tissuesFigure 1
Expression of the ITIH gene family and AMBP and 
TNFAIP6 genes in normal human tissues. RNA 
expression analysis using Clontech's Multiple Tissue North-
ern (MTN) blot demonstrates specificity and correct tran-
script size of the respective gene probes later used for dot 
blot analysis. See text for details.Page 6 of 15
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ties (Figure 2). These differential expression patterns
nearly exclusively presented as loss of ITIH mRNAs in
tumor tissues. An overview of the complete expression
data is provided in Table 4. In contrast to the highly dif-
ferential expression of ITIH genes, AMBP and TNFAIP6
exhibited a much broader expression pattern with differ-
ential gene expression restricted to kidney tissue. In detail,
the expression patterns of the analyzed genes on the CPA
presented as follows:
ITIH2 mRNA expression was detectable in normal breast,
uterus, ovary, lung and kidney tissues with little expres-
sion in the other eight tissues analyzed. Loss or downreg-
ulation of ITIH2 expression was seen in 70% of breast
cancers, 71% of lung cancers, and 70% of renal tumors
(see Figure 2A). Additionally, careful densitometric evalu-
ation of the hybridization signals showed downregulation
in 56% of gastric cancers, 61% of rectal carcinomas, and
50% of prostate cancers.
ITIH3 mRNA expression was detectable in normal breast,
uterus, colon, stomach, ovary, lung, kidney and rectum
(Figure 2B). Downregulation of ITIH3 expression was
seen in cancers of the breast (51%), uterus (62%), colon
(67%), ovary (71%), lung (86%), rectum (72%), and
prostate (4 out of 4 samples).
ITIH4 mRNA was detectable in normal breast, uterus,
stomach, ovary and lung (see Figure 2C). Expression is
especially abundant in the normal kidney, very much in
accordance with the Northern blot data (Figure 1) and
thus clearly demonstrating that dot blot analysis of spot-
ted cDNAs (CPA analysis) is much more sensitive than
Northern blot hybridization of poly A+ RNAs. ITIH4
mRNA was only weakly expressed in normal colon, rec-
tum, and small intestine. Downregulation of ITIH4 in
cancer tissue was detectable in tumors of the kidney
(95%), stomach (63%) and ovary (57%) as well as in
colon cancer (54%), lung cancer (52%), rectum cancer
(50%), and prostate cancer (75%).
ITIH5 mRNA was detectable in normal breast, uterus,
colon and kidney. MTN expression data has been pub-
lished before, showing strong expression in placenta and
lower expression in mammary gland and ovary [7]. How-
ever, a significant downregulation of ITIH5 expression
(52%) was observed in breast cancer only (Figure 2D).
AMBP is abundantly expressed in all 13 tissues repre-
sented on the CPA. A prominent downregulation of 90%
was detectable in kidney cancer (Figure 2E). TNFAIP6 is
very abundantly expressed in several normal tissues like
breast, lung, colon, uterus and rectum. A highly signifi-
cant upregulation of TNFAIP6 mRNA expression was
observed in kidney cancer in 91% of cases (Figure 2F). A
clear TNFAIP6 upregulation below the defined cut-off of
50% was furthermore detectable in tumors of the ovary
and stomach (43% and 48%, respectively).
Differential expression analysis of ITIH2 downregulation 
in breast cancer using Reverse Transcriptase PCR (RT-
PCR)
As the main focus of our workgroups lies on molecular
understanding of breast cancer, we chose ITIH2 for a
detailed expression analysis in human breast cancer. To
provide further evidence that ITIH2 mRNA is differen-
tially expressed in breast cancer we performed a semi-
quantitative real-time PCR analysis on a cohort of 36
primary breast carcinomas. The relative ITIH2 expression
level of each specimen was normalized against expression
of a non-malignant breast tissue cDNA and calculated as
fold change-value of tumor tissue versus normal tissue. A
fold change > 2 (FC2) was considered as being deregula-
tion of normal ITIH2 expression. Due to this cut-off, 23
out of 36 breast tumor specimens exhibited ITIH2 down-
regulation (63.9%) by FC2, whereas 13 out of 36 speci-
mens (36.1%) showed no deregulation or upregulation of
ITIH2 (Figure 3). In line with the results derived from the
CPA, ITIH2 mRNA downregulation in breast cancer could
thus be confirmed by a second independent technique.
Immunohistochemistry of ITIH2 expression in invasive 
carcinomas
Immunohistochemical analysis was applied to compare
ITIH2 protein expression in normal and malignant breast
tissue. A tissue microarray containing 185 invasive breast
carcinomas, 2 carcinomas in-situ (DCIS), and 28 normal
breast tissue samples was used. Intensity and quantity of
immunohistochemical staining was evaluated using a
semiquantitative immunoreactivity score (IRS) [47].
ITIH2 expression was clearly detectable in the epithelium
of normal breast tissue (Figure 4A and 4B). ITIH2 expres-
sion was maintained in hyperplastic gland epithelium
and ductal carcinoma in-situ (DCIS), however, ITIH2
expression was somewhat weaker in DCIS than in normal
tissue (Figure 4C and 4D). In 44% (81/185) of invasive
carcinomas of the breast, ITIH2 expression was strongly
reduced or completely lost (Figure 4E and 4F) while 56%
of invasive carcinomas (104/185) maintained moderate
to strong ITIH2 expression (Figure 4G and 4H).
ITIH2 expression was also studied on whole tissue sec-
tions of invasive tumors. In case of abundant expression,
ITIH2 was homogeneously distributed across the tumor
masses and showed neither a patchy expression pattern,
nor a particular concentration at the tumor invasion front
(data not shown).Page 7 of 15
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Differential expression of the ITIH gene family in 13 different human tumor entitiesFigu  2
Differential expression of the ITIH gene family in 13 different human tumor entities. Gene probes for ITIH genes, 
as well as the AMBP and TNFAIP6 genes, were hybridized to a Cancer Profiling Array (Clontech, Heidelberg, Germany) contain-
ing spotted cDNAs from 241 human tumors and 241 corresponding human normal tissues. See text for details and Table 4 for 
a detailed densitometric evaluation of the hybridization signals.
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For descriptive data analysis, we associated clinicopatho-
logical data with ITIH2 expression status, categorizing
ITIH2 expression according to immunoreactivity score
(IRS) into weak to no expression (0–5) versus moderate to
strong expression (6–12). The complete statistical data are
provided in Table 5. In Fisher's two-sided exact test, strong
ITIH2 expression was highly significantly associated with
presence of the estrogen receptor (p = 0.001).
Furthermore, overall survival (OS) and recurrence-free
survival (RFS) were compared between tumors with weak
versus tumors with strong immunoreactivity using univar-
iate log-rank statistics in Kaplan-Meier analysis (Figure 5).
Loss of ITIH2 expression was not significantly associated
with shorter overall survival (p = 0.386) or recurrence-free
survival (p = 0.948). Moreover, in a stratified Kaplan-
Meier analysis, there was no significant association
between loss of ITIH2 expression and shorter overall sur-
vival for patients with versus patients without lymph node
invasion (p = 0.492 and p = 0.547, respectively), neither
for ER-positive versus ER-negative patients (p = 0.358 and
p = 0.359, respectively). Similarly, loss of ITIH2 expres-
sion was not significantly associated with shorter recur-
rence-free survival for patients with versus patients without
lymph node invasion (p = 0.478 and p = 0.243, respec-
tively), neither for ER-positive versus ER-negative patients
(p = 0.312 and p = 0.931, respectively).
Discussion
The family of inter-alpha-trypsin inhibitors (also named
inter-alpha (globulin) inhibitors) is a long-known family
of serine protease inhibitors, composed of a light chain
with anti-proteolytic activity (bikunin) and different
homologous heavy chains (ITIHs), which contribute to
the stability of the extracellular matrix. There have been
many studies on biological effects of the ITI molecules,
proposing an involvement in various acute-phase proc-
esses, such as inflammation or cancer. However, there has
been no approach to systematically identify expression
patterns of ITIs in human tumors in order to reveal poten-
tial candidate tumor suppressor genes and/or oncogenes.
In our present study, we address the issue of differential
gene expression of the ITI genes, using Cancer Profiling
Arrays containing spotted cDNAs from 241 tumor and
ITIH2 mRNA expression analysis as determined by real-time PCRFigure 3
ITIH2 mRNA expression analysis as determined by 
real-time PCR. 36 breast carcinoma specimens were ana-
lyzed. Each tumor expression level was calculated as fold 
change expression versus a normal breast tissue cDNA (set 
to 1 on y-axis). 23/36 samples (64%) exhibited a substantial 
reduction of ITIH2 mRNA, indicated by an expression fold 
change of >2 in the tumor tissue, thus were scored as being 
downregulated (black bars) whereas grey bars represent 
specimens with non-deregulated or upregulated ITIH2 
expression.
Table 4: Frequent loss of ITIH expression in multiple human solid tumors.
Tissue n ITIH1 
regulation (%)
ITIH2 
regulation (%)
ITIH3 
regulation (%)
ITIH4 
regulation (%)
ITIH5 
regulation (%)
AMBP 
regulation (%)
TNFAIP6 
regulation (%)
up down up down up down up down up down up down up down
Breast 50 2 6 2 70 9 51 6 16 6 52 4 10 6 35
Uterus 42 0 10 12 26 5 62 7 29 5 24 0 7 21 13
Colon 35 11 9 11 43 9 67 9 54 3 40 3 0 31 31
Stomach 27 7 19 30 56 12 38 4 63 15 19 0 37 48 12
Ovary 14 7 14 18 27 21 71 14 57 0 21 21 7 43 29
Lung 21 0 0 0 71 0 86 10 52 0 14 5 5 0 30
Kidney 20 0 35 0 70 10 35 0 95 15 0 0 90 91 0
Rectum 18 0 11 22 61 6 72 6 50 11 22 6 11 13 25
Thyroid 6 0 0 17 17 0 50 17 33 0 17 0 17 n.e.
Prostate 4 50 25 0 50 0 100 0 75 0 0 0 25 n.e.
Densitometric analysis of hybridization signals shown in Fig. 2. Percentages of deregulation (two-fold up- or down-regulation according to the well-
established fold change two approach, FC2) in the given tumor entity (n.e. = not expressed). Fold changes between 0.5 and 2.0 were considered as 
not differentially expressed and are represented as the missing percentages to 100% in each tumor entity. Only tumor entities with four or more 
samples (n ≥ 4) on the CPA were considered for densitometric evaluation.Page 9 of 15
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ITIH2 immunohistochemistry on TMA derived from normal and cancerous breast tissueFigure 4
ITIH2 immunohistochemistry on TMA derived from normal and cancerous breast tissue. A+B: Strong cytoplas-
mic staining is seen in normal epithelial cells of the mammary gland. C+D: Ductal carcinoma in-situ (high grade type) with mod-
erate focal cytoplasmic staining and normal, partially hyperplastic gland epithelium with strong cytoplasmic staining (see 
arrows). E-H: Invasive ductal carcinoma with either negative (E, F) or strong ITIH2 staining (G, H). Magnification: 100× (A, C, E, 
G), 400× (B, D, F, H).
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ferent human tumor entities. Therefore, in this study we
present for the first time systematic expression patterns of
ITIH genes in a broad panel of human normal and tumor
tissue samples.
Our findings clearly show a strongly deregulated expres-
sion pattern in multiple human solid tumors for all ITIH
genes except for ITIH1. In fact, deregulation exclusively
presented as downregulation with different patterns for
the ITIH genes in human tumor entities. Therefore, ITIH
genes may represent putative tumor suppressor genes that
should be studied in greater detail in further studies. Also,
we clearly demonstrated that ITIH gene expression is not
limited to liver as the main site of posttranslational mod-
ifications, although expression in liver by far exceeds
mRNA quantities in any other tissue (except for ITIH5,
which is most strongly expressed in placenta). These find-
ings match the rare quantitative expression data of previ-
ous studies, using RT-PCR to determine expression levels
of ITIH mRNA[49].
For a further analysis of ITIH expression on the protein
level, we selected ITIH2 expression in normal and malig-
nant breast tissue, since out of all ITIH family members,
ITIH2 showed the most frequent downregulation (70%)
in this tumor entity. Investigating ITIH2 expression in
human breast cancer we were able to confirm the data
obtained by CPA analysis (70% downregulation) by sem-
iquantitative real-time RT-PCR (64% downregulation) in
an additional set of breast tumors. Thus, CPA analysis
proved to be a valid method for detecting differential gene
expression in a systematic screening approach, as we were
previously able to demonstrate[39,50]. Next, we analyzed
for the first time ITIH2 protein expression in normal
breast tissue and breast cancer. ITIH2 expression was
highly significantly correlated with expression of the
estrogen receptor (p = 0.001). Though estrogen is known
to inhibit invasion and motility in breast cancer [51], the
Table 5: Clinicopathological and immunohistochemical parameters in relation to cytoplasmic ITIH2 immunoreactivity
Variable Categorization ITIH2 immunoreactivity Tumor-related death Tumor recurrence
n analyzable weak strong p3 n events p4 n events p4
Clinicopathological factor:
Tumor stage1
pT1 46 19 27 0.875 46 7 <0.001 45 10 <0.001
pT2 92 43 49 92 32 89 41
pT3 13 5 8 13 6 12 6
pT4 30 12 18 30 19 27 19
Lymph node status1
pN0 71 30 41 0.757 71 12 <0.001 69 14 <0.001
pN1–3 104 47 57 104 47 100 57
Histological grade
low grade (G1 – G2) 100 40 60 1.000 100 26 <0.001 95 33 <0.001
high grade (G3) 80 38 42 80 38 78 42
Histological type
ductal 145 61 84 0.915 145 51 0.772 142 65 0.371
lobular 13 5 8 13 6 11 4
other 19 9 10 19 6 17 5
Immunohistochemistry (IHC):
Estrogen receptor status
negative (IRS2 0–2) 49 30 19 0.001 49 21 0.080 49 25 0.096
positive (IRS 3–12) 97 31 66 97 29 93 33
Progesterone receptor status
negative (IRS2 0–2) 107 44 63 0.862 107 48 0.001 101 50 0.008
positive (IRS 3–12) 49 21 28 49 9 49 13
HER2 expression status
negative 120 53 67 0.190 120 33 <0.001 113 43 0.007
positive 38 12 26 38 22 38 22
P-values according to Fisher's exact test (two-sided) were calculated for significance of correlation between clinicopathological and 
immunohistochemical parameters in relation to cytoplasmatic ITIH2 immunoreactivity. Furthermore, univariate analysis of factors regarding tumor-
specific survival and recurrence-free survival was performed with significance calculated by log rank test (two-sided).
1According to UICC: TNM Classification of Malignant Tumours (2002) [65]. 2IRS = Immunoreactivity score according to Remmele and Stegner 
(1987) [47]. 3Fisher's exact test (two-sided). 4Log-rank test (two-sided). Bold face representing significant data (p < 0.05).Page 11 of 15
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Since estrogen is known to influence extracellular matrix
(ECM) integrity in responsive organs like uterus or
vagina[52], estrogen could have a profound effect on ITIH
molecules in normal and pathological breast tissues as
well. In silico analysis of the ITIH2 gene promoter (-3500
to +200) revealed the presence of at least two estrogen
receptor binding motifs (as predicted by Genomatix[53]),
although the most common Estrogen Response Element
(ERE) consensus sequence GGTCAnnnTGACC[54] was
not found in this region. Nevertheless, Stender et al[55]
showed that ER responsive MCF7 breast cancer cells
respond to stimulation with ectopic estrogen by upregula-
tion of ITIH2 expression in a time- and dose-dependent
manner. This functional relationship is a subject of future
studies to confirm our in vivo findings in an in vitro cell
culture model. Also, it will be important to generate anti-
bodies for the remaining ITIH family members in order to
investigate their protein expression patterns as well as pos-
sible hormonal regulation in different human tumor enti-
ties.
In spite of a remarkably strong downregulation of the
ITIH molecules in a variety of human solid tumors, we
were not able to demonstrate a statistically significant
association between loss of ITIH2 expression in breast
cancer and reduced overall survival (p = 0.386) or shorter
recurrence-free survival (p = 0.948) in Kaplan-Meier anal-
ysis. Likewise, there was no statistically significant correla-
tion between loss of ITIH2 expression and reduced overall
survival or recurrence-free survival, respectively, in a sub-
group analysis for node status and estrogen receptor sta-
tus. However, looking at expression patterns of the
different heavy chain genes, there may be redundancy in
their tumor suppressive functions, as e.g. ITIH2 and ITIH5
are both abundantly expressed in normal breast tissue.
Recent studies in our workgroup revealed ITIH5 to be a
novel prognostic marker in invasive node-negative breast
cancer [37], proposing possible redundant functions of
the structurally and genetically (ITIH2 and ITIH5 are both
located on chromosome 10p15) related ITIH molecules.
Altogether, the close association between ITIH2 and
ITIH5, and their strong correlation with the estrogen
receptor status, suggest that these molecules interact in
their tumor-suppressive and metastasis-repressive proper-
ties.
Based on the knowledge of biological functions of ITIs,
our data raise the hypothesis that these genes may exhibit
tumor-suppressive properties on various levels of carcino-
genesis. For many years, extracellular proteolysis has been
known to be involved in development and spreading of
cancer. However, the molecules contributing to the total
proteolytic activity form a highly heterogenic group, to
this date preventing efforts to present a wholistic concept.
Even looking at subsets of proteases, such as the tissue kal-
likrein gene family, reveals the complex interaction of
related enzymes[56]. Still, there is no question on the
importance to understand and evaluate influences on
extracellular proteolysis [57]. The ITI light chain, bikunin,
has been identified previously to have anti-metastatic
properties [58]). In particular, bikunin represses cell-
bound plasmin activity [32,33] and is thought to inhibit
CD44 dimerization and suppress the MAP kinase signal-
ling cascade[58], thus preventing ECM degradation,
tumor cell invasion, and angiogenesis.
Inhibition of tumor growth and spreading mediated by
ITIH genes most likely relates to their stabilizing effects on
the extracellular matrix, as well as their covalent linkage of
hyaluronic acid (HA). In tissue remodelling, which is cru-
cial to tumor growth and metastasis, hyaluronic acid turn-
over may play a key role. West and Kumar[59] reviewed
the influence of hyaluronan on endothelial cells and neo-
vascularization and concluded that HA degradation prod-
ucts may induce angiogenesis. Since HA linking and ECM
stability is strongly dependent on ITI heavy chains, dereg-
ulation of ITIH family members should influence the vas-
cularization process during tumor development. In
particular, tumor suppressive effects have been attributed
to the ITIH genes before: The short arm of chromosome 3
(3p), which ITIH1, ITIH3, and ITIH4 map to (see Table
1), is known to be a site of frequent genetic alterations in
the evolvement of various human cancers (e.g. renal cell
carcinoma[60], lung carcinoma[61], and others). In fact,
in a survey on head and neck cancers, it has been pro-
Kaplan-Meier analysis of patients' overall survival (OS) with respect to ITIH2 expression statusFigure 5
Kaplan-Meier analysis of patients' overall survival 
(OS) with respect to ITIH2 expression status. Cumula-
tive survival is presented on the y-axis, tick marks represent 
censored patients.Page 12 of 15
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which harbours several tumor-suppressor genes[62]. Fur-
thermore, ITIH3 has been shown to be a downstream tar-
get of Sonic hedgehog (Shh)[63], which itself is know to
be involved in pathogenesis of some human cancers, e.g.
skin and brain cancers[64]. Investigating the interference
of ITIH molecules and Shh may present a promising
approach to elucidate functional interactions of ITI heavy
chains. Finally, ITIH1 and ITIH3 have been shown to
increase cell attachment and to reduce the number of lung
cancer metastases in mice [36].
Altogether, our systematic ITIH expression analysis dem-
onstrates that this gene family may harbour some promis-
ing new candidate tumor suppressor genes. Further
studies will be needed to identify specific tumor entities
and clinical settings, in which ITIH genes may serve as
novel prognostic markers and possible therapeutic targets.
Conclusion
In summary, our systematic analysis of differential gene
expression in the family of inter-alpha-trypsin inhibitors
leads to the following conclusions: ITIH2, ITIH3, ITIH4,
and ITIH5 are strongly downregulated in a variety of
human solid tumors (see Fig. 2, Table 4); therefore, the
ITIH genes are potential candidates as tumor suppressor
or metastasis repressor genes. Thus, ITIH molecules may
serve as potential diagnostic markers or therapeutic targets
in the malignant setting. Further studies will be needed to
elucidate molecular pathways and biochemical interac-
tions of the ITIH family, as well as their involvement in
tumorigenesis and spreading of cancer.
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